Nuwellis Names Mike McCormick CEO Effective June 30, 2026
NUWE•Mike McCormick will become CEO of Nuwellis on June 30, 2026, with founder John Erb shifting to Chairman of the Board. McCormick brings over 30 years in medical technology leadership and will focus on accelerating commercial execution, advancing the cardiorenal pipeline and enhancing shareholder value.
1. Leadership Transition
On June 30, 2026, Mike McCormick will assume the role of Chief Executive Officer at Nuwellis, while current CEO John Erb transitions to Chairman of the Board. This move maintains board continuity while injecting new operational leadership at the executive level.
2. Executive Background
McCormick has over three decades of experience in medical technology, having founded, scaled and led multiple public and private healthcare companies. He served as an independent director at Nuwellis from June 2023 through January 2026, bringing expertise in product commercialization and corporate strategy.
3. Strategic Focus
Under McCormick’s leadership, the company aims to strengthen its precision fluid management offerings for cardiorenal care, accelerate commercial execution of existing products and advance its development-stage pipeline. The new CEO will prioritize capital formation and strategic transactions to drive long-term growth and value creation.
